GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CTKB · Jun 30, 2026

Cytek Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration

State dimensions

Filing0001628280-26-053496General Corporate
Capex intensity89thOwn-history percentile · N=19
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

4.60% · OPTIONAL · VALID

Operating cash generation58thOwn-history percentile · N=19
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

2.84% · OPTIONAL · VALID

Revenue growth38thOwn-history percentile · N=16
Evidence method

Yoy · gp.fundamentals.revenue

5.57% · CORE · VALID

Inventory pressure60thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

108.54% · OPTIONAL · VALID

Gross margin70thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

58.87% · CORE · VALID

Operating margin20thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-23.68% · CORE · VALID

R&D intensity35thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

20.23% · OPTIONAL · VALID

SBC intensity45thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

11.09% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History21 statesSelf-history eligible
Sep 30, 20210/7 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/8 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20235/8 normalizedLevel 3Sep 30, 20237/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
4.91%
Current
4.60%
Delta
-0.31%
Cash Generation Increased
Previous
-6.20%
Current
2.84%
Delta
9.04%
Growth Decreased
Previous
6.46%
Current
5.57%
Delta
-0.89%
Inventory Pressure Decreased
Previous
112.82%
Current
108.54%
Delta
-4.28%
Margin Increased
Previous
48.16%
Current
58.87%
Delta
10.71%
Profitability Increased
Previous
-41.83%
Current
-23.68%
Delta
18.15%
R And D Intensity Decreased
Previous
21.76%
Current
20.23%
Delta
-1.53%
Sbc Intensity Increased
Previous
11.01%
Current
11.09%
Delta
0.08%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Jun 30, 2025
Similarity
72%
Compared
8 dimensions
Coverage
100%
Growth 20.8 · Margin 57.5 · Profitability 1.3 · Sbc Intensity 42.5 · Capex Intensity 2.8 · Cash Generation 17.9 · R And D Intensity 16.3 · Inventory Pressure 3.8
Mar 31, 2026
Similarity
70%
Compared
8 dimensions
Coverage
100%
Growth 9.2 · Margin 70.0 · Profitability 20.0 · Sbc Intensity 2.9 · Capex Intensity 5.0 · Cash Generation 30.1 · R And D Intensity 28.2 · Inventory Pressure 8.4
Dec 31, 2023
Similarity
62%
Compared
7 dimensions
Coverage
88%
Margin 50.0 · Profitability 0.0 · Sbc Intensity 25.0 · Capex Intensity 67.3 · Cash Generation 2.3 · R And D Intensity 25.0 · Inventory Pressure 40.0
Sep 30, 2024
Similarity
58%
Compared
8 dimensions
Coverage
100%
Growth 15.3 · Margin 54.6 · Profitability 26.2 · Sbc Intensity 47.3 · Capex Intensity 72.8 · Cash Generation 42.1 · R And D Intensity 19.6 · Inventory Pressure 21.5
Jun 30, 2023
Similarity
55%
Compared
5 dimensions
Coverage
63%
Margin 70.0 · Profitability 7.5 · Sbc Intensity 42.5 · R And D Intensity 52.5 · Inventory Pressure 27.5
Research Graph

Related governed research

Analogous To · CTKB state analogue 1 →Analogous To · CTKB state analogue 5 →Compared To · Laboratory Analytical Instruments peers →Analogous To · CTKB state analogue 2 →Analogous To · CTKB state analogue 3 →Analogous To · CTKB state analogue 4 →Transitioned To · CTKB Fundamental State →Transitioned To · CTKB CAPEX_INTENSITY_DECREASED →Transitioned To · CTKB CASH_GENERATION_INCREASED →Transitioned To · CTKB GROWTH_DECREASED →Transitioned To · CTKB INVENTORY_PRESSURE_DECREASED →Transitioned To · CTKB MARGIN_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.